JP2006094827A - 血小板分化を調節する因子の同定方法 - Google Patents
血小板分化を調節する因子の同定方法 Download PDFInfo
- Publication number
- JP2006094827A JP2006094827A JP2004287226A JP2004287226A JP2006094827A JP 2006094827 A JP2006094827 A JP 2006094827A JP 2004287226 A JP2004287226 A JP 2004287226A JP 2004287226 A JP2004287226 A JP 2004287226A JP 2006094827 A JP2006094827 A JP 2006094827A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- megakaryocyte
- megakaryocytes
- platelets
- differentiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 106
- 230000004069 differentiation Effects 0.000 title claims abstract description 85
- 210000003593 megakaryocyte Anatomy 0.000 claims abstract description 208
- 210000004027 cell Anatomy 0.000 claims abstract description 165
- 108010067306 Fibronectins Proteins 0.000 claims description 56
- 102000016359 Fibronectins Human genes 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 230000001737 promoting effect Effects 0.000 abstract 3
- 230000001939 inductive effect Effects 0.000 abstract 1
- 102000036693 Thrombopoietin Human genes 0.000 description 68
- 108010041111 Thrombopoietin Proteins 0.000 description 68
- 102100037362 Fibronectin Human genes 0.000 description 54
- 230000008569 process Effects 0.000 description 44
- 230000004660 morphological change Effects 0.000 description 32
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 210000001185 bone marrow Anatomy 0.000 description 23
- 239000000243 solution Substances 0.000 description 19
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 17
- 239000002609 medium Substances 0.000 description 15
- 230000006698 induction Effects 0.000 description 14
- 229960001134 von willebrand factor Drugs 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 12
- 239000006285 cell suspension Substances 0.000 description 12
- 210000002361 Megakaryocyte Progenitor Cell Anatomy 0.000 description 10
- 229940098773 bovine serum albumin Drugs 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 9
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 210000002798 bone marrow cell Anatomy 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 206010043554 thrombocytopenia Diseases 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000012879 subculture medium Substances 0.000 description 6
- 102000004338 Transferrin Human genes 0.000 description 5
- 108090000901 Transferrin Proteins 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000012581 transferrin Substances 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 108010047303 von Willebrand Factor Proteins 0.000 description 5
- 102100036537 von Willebrand factor Human genes 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 208000005485 Thrombocytosis Diseases 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 229920001342 Bakelite® Polymers 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 238000011419 induction treatment Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000003147 molecular marker Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 102000055157 Complement C1 Inhibitor Human genes 0.000 description 1
- 108700040183 Complement C1 Inhibitor Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101710149643 Integrin alpha-IIb Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000034311 endomitotic cell cycle Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004287226A JP2006094827A (ja) | 2004-09-30 | 2004-09-30 | 血小板分化を調節する因子の同定方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004287226A JP2006094827A (ja) | 2004-09-30 | 2004-09-30 | 血小板分化を調節する因子の同定方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006094827A true JP2006094827A (ja) | 2006-04-13 |
| JP2006094827A5 JP2006094827A5 (enExample) | 2007-10-11 |
Family
ID=36235225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004287226A Pending JP2006094827A (ja) | 2004-09-30 | 2004-09-30 | 血小板分化を調節する因子の同定方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2006094827A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011142457A1 (ja) | 2010-05-14 | 2011-11-17 | 国立大学法人熊本大学 | 血球成熟促進活性を有する物質のスクリーニング方法 |
-
2004
- 2004-09-30 JP JP2004287226A patent/JP2006094827A/ja active Pending
Non-Patent Citations (3)
| Title |
|---|
| JPN6010034995, Ｂｌｏｏｄ， ８７［１１］ （１９９６） ｐ．４５５２−４５６０ * |
| JPN6010034996, Ｂｌｏｏｄ， ９９［１０］ （２００２） ｐ．３５７９−３５８４ * |
| JPN6010035000, Ｂｌｏｏｄ， ９２［８］ （１９９８） ｐ．２６５０−２６５６ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011142457A1 (ja) | 2010-05-14 | 2011-11-17 | 国立大学法人熊本大学 | 血球成熟促進活性を有する物質のスクリーニング方法 |
| EP2570483A4 (en) * | 2010-05-14 | 2013-10-09 | Univ Kumamoto Nat Univ Corp | PROCESS FOR SCREENING TO SUBSTANCES WITH BLOOD CELL MATERIAL IMPROVEMENT |
| US9766227B2 (en) | 2010-05-14 | 2017-09-19 | Bloom Technology Co., Ltd. | Screening method for substance having hemocyte maturation acceleration action |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7373872B2 (ja) | 初代乳房上皮細胞培養培地、培養方法、及びその使用 | |
| JP7461674B2 (ja) | 食道扁平上皮癌の上皮細胞用の培養培地、培養方法、及びその用途 | |
| Metcalf | Hemopoietic colonies: in vitro cloning of normal and leukemic cells | |
| Prasain et al. | Phenotypic and functional characterization of endothelial colony forming cells derived from human umbilical cord blood | |
| US20200071676A1 (en) | Three-dimensional culture of primary cancer cells using tumor tissue | |
| JP2003513664A (ja) | ヒト胚性幹細胞の造血分化 | |
| Miller et al. | Human and mouse hematopoietic colony-forming cell assays | |
| Jiang et al. | Fibronectin-and protein kinase C–mediated activation of ERK/MAPK are essential for proplateletlike formation | |
| NL2027546B1 (en) | Method of producing an organoid | |
| De Groot et al. | Establishment of microglial cell cultures derived from postmortem human adult brain tissue: immunophenotypical and functional characterization | |
| Dolznig et al. | Expansion and differentiation of immature mouse and human hematopoietic progenitors | |
| Schulze | Culture, expansion, and differentiation of murine megakaryocytes from fetal liver, bone marrow, and spleen | |
| JP5758891B2 (ja) | 筋線維芽細胞を取得する方法 | |
| CN114246883A (zh) | 一种药物组合物及其治疗剂和应用 | |
| Unchern | Basic techniques in animal cell culture | |
| CZ301148B6 (cs) | Zpusob pestování lidských mezenchymových kmenových bunek, zejména pro lécbu nehojících se fraktur, a bioreaktor k provádení tohoto zpusobu | |
| US20250186505A1 (en) | Methods of Determining the Suitability of Cultured Thymus Tissue for Implantation Into Humans and Associated Methods of Use | |
| Smith et al. | Isolation of CD31+ bone marrow endothelial cells (BMECs) from mice | |
| JPH0372872A (ja) | 無血清培地及びそれを用いた哺乳類細胞の培養法 | |
| Catanuto et al. | Mouse retinal pigmented epithelial cell lines retain their phenotypic characteristics after transfection with human papilloma virus: a new tool to further the study of RPE biology | |
| Rubio et al. | Generation of mosaic mammary organoids by differential trypsinization | |
| CN107460170B (zh) | 人垂体腺瘤细胞系的建立及其应用 | |
| Hai et al. | Efficient method to differentiate mouse embryonic stem cells into macrophages in vitro | |
| Solà et al. | Primary cultures for neurotoxicity testing | |
| Ponyatovskaya et al. | Transplant of limbal epithelial stem cells on bioresorbable scaffold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070824 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070824 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20070824 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100618 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100810 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100916 |